These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 6996844)

  • 1. [Protective effect of coli-proteus vaccine in an experimental animal model].
    Bĕlohlávek S; Konícková L
    Cesk Farm; 1980 May; 29(3-4):95-9. PubMed ID: 6996844
    [No Abstract]   [Full Text] [Related]  

  • 2. Transurethral instillation with fusion protein MrpH.FimH induces protective innate immune responses against uropathogenic Escherichia coli and Proteus mirabilis.
    Habibi M; Asadi Karam MR; Bouzari S
    APMIS; 2016 Jun; 124(6):444-52. PubMed ID: 26918627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of urinary tract infections with SolcoUrovac].
    Litschgi M
    Geburtshilfe Frauenheilkd; 1987 Feb; 47(2):107-10. PubMed ID: 3106132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of vaccination in urinary infections caused by Escherichia coli in rats].
    Mathieu D; Jacques L; Auer J; Bizzini B
    Biomed Pharmacother; 1987; 41(8):442-5. PubMed ID: 3330459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ascending to a UTI vaccine?
    Clarkson S
    Nat Rev Microbiol; 2004 Feb; 2(2):90. PubMed ID: 15040255
    [No Abstract]   [Full Text] [Related]  

  • 6. Native flagellin does not protect mice against an experimental Proteus mirabilis ascending urinary tract infection and neutralizes the protective effect of MrpA fimbrial protein.
    Scavone P; Umpiérrez A; Rial A; Chabalgoity JA; Zunino P
    Antonie Van Leeuwenhoek; 2014 Jun; 105(6):1139-48. PubMed ID: 24771125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antireflux ureteroileal anastomoses: two experimental technique.
    Starr A; Rose DH; Cooper JF; Snyder RN
    Invest Urol; 1974 Nov; 12(3):165-71. PubMed ID: 4613686
    [No Abstract]   [Full Text] [Related]  

  • 8. Development of an intranasal vaccine to prevent urinary tract infection by Proteus mirabilis.
    Li X; Lockatell CV; Johnson DE; Lane MC; Warren JW; Mobley HL
    Infect Immun; 2004 Jan; 72(1):66-75. PubMed ID: 14688082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination to Protect Against Proteus mirabilis Challenge Utilizing the Ascending Model of Urinary Tract Infection.
    Smith SN; Himpsl SD; Mobley HLT
    Methods Mol Biol; 2019; 2021():201-215. PubMed ID: 31309507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Indication of coli-vaccine in urinary tract infectious during pregnancy].
    Vojta M; Balák K; Závadová M; Bĕlohlávek V
    Cesk Gynekol; 1973; 38(1):68-70. PubMed ID: 4580871
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral vaccination against Porteus mirabilis.
    Jones RJ
    Br J Exp Pathol; 1976 Aug; 57(4):395-9. PubMed ID: 822863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasal immunization with attenuated Salmonella Typhimurium expressing an MrpA-TetC fusion protein significantly reduces Proteus mirabilis colonization in the mouse urinary tract.
    Scavone P; Umpiérrez A; Maskell DJ; Zunino P
    J Med Microbiol; 2011 Jul; 60(Pt 7):899-904. PubMed ID: 21415205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of active and passive antibacterial immunization on skin allograft survival in rabbits.
    Liska M; Hatala M
    Folia Biol (Praha); 1979; 25(1):70-5. PubMed ID: 107050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of immunization with Escherichia coli J5 on the course of experimental pyelonephritis in rats].
    Straube E; Naumann G; Broschewitz U
    Z Urol Nephrol; 1988 Apr; 81(4):247-55. PubMed ID: 3041706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections.
    Pellegrino R; Galvalisi U; Scavone P; Sosa V; Zunino P
    FEMS Immunol Med Microbiol; 2003 May; 36(1-2):103-10. PubMed ID: 12727373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis.
    Li X; Erbe JL; Lockatell CV; Johnson DE; Jobling MG; Holmes RK; Mobley HL
    Infect Immun; 2004 Dec; 72(12):7306-10. PubMed ID: 15557656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The protective effect of an EDTA-sodium-extract-vaccine obtained from swine-pathogenic E. coli in a field trial. 2. Communication: Immunization of weanling piglets (author's transl)].
    Mochmann H; Zwierzchowski J; Hering L; Molenda J; Ocklitz HW; Bocianowski M; Austenat L; Wałachowski W; Janas Z
    Zentralbl Bakteriol A; 1980; 247(2):208-20. PubMed ID: 6775450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral immunization against coli enteritis with streptomycin-dependent E. coli. IV. Tolerance of a streptomycin-dependent O111 B4 bacterial vaccine in infants].
    Köditz H; Kittlick M; Linde K; Koch H
    Zentralbl Bakteriol Orig; 1969; 211(4):486-93. PubMed ID: 4916989
    [No Abstract]   [Full Text] [Related]  

  • 19. A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic Escherichia coli.
    Billips BK; Yaggie RE; Cashy JP; Schaeffer AJ; Klumpp DJ
    J Infect Dis; 2009 Jul; 200(2):263-72. PubMed ID: 19522648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fimbriae of uropathogenic Proteus mirabilis.
    Rocha SP; Pelayo JS; Elias WP
    FEMS Immunol Med Microbiol; 2007 Oct; 51(1):1-7. PubMed ID: 17640292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.